Screener
CytomX Therapeutics CTMX Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's current ratio?
- CytomX Therapeutics (CTMX) reported current ratio of 9.4× in Q2 2026.
- How has CytomX Therapeutics's current ratio changed year-over-year?
- CytomX Therapeutics's current ratio increased by 123.0% year-over-year, from 4.2× to 9.4×.
- What is the long-term trend for CytomX Therapeutics's current ratio?
- Over 5 years (2020 to 2025), CytomX Therapeutics's current ratio has grown at a -8.3% compound annual growth rate (CAGR), from 4.8× to 3.1×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about CytomX Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude